Literature DB >> 29211296

"Epigenetic" modification as therapy for acute myeloid leukemia.

Charles A Schiffer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29211296      PMCID： PMC6871512          DOI： 10.1002/cncr.31137

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  11 in total

1.  A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements.

Authors:  Allen S Yang; Marcos R H Estécio; Ketan Doshi; Yutaka Kondo; Eloiza H Tajara; Jean-Pierre J Issa
Journal:  Nucleic Acids Res       Date:  2004-02-18       Impact factor: 16.971

2.  "I am older, not elderly," said the patient with acute myeloid leukemia.

Authors:  Charles A Schiffer
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

3.  Genomic Classification in Acute Myeloid Leukemia.

Authors:  Elli Papaemmanuil; Hartmut Döhner; Peter J Campbell
Journal:  N Engl J Med       Date:  2016-09-01       Impact factor: 91.245

4.  Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.

Authors:  Hagop M Kantarjian; Gail J Roboz; Patricia L Kropf; Karen W L Yee; Casey L O'Connell; Raoul Tibes; Katherine J Walsh; Nikolai A Podoltsev; Elizabeth A Griffiths; Elias Jabbour; Guillermo Garcia-Manero; David Rizzieri; Wendy Stock; Michael R Savona; Todd L Rosenblat; Jesus G Berdeja; Farhad Ravandi; Edwin P Rock; Yong Hao; Mohammad Azab; Jean-Pierre J Issa
Journal:  Lancet Oncol       Date:  2017-08-24       Impact factor: 41.316

5.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Authors:  Hagop M Kantarjian; Xavier G Thomas; Anna Dmoszynska; Agnieszka Wierzbowska; Grzegorz Mazur; Jiri Mayer; Jyh-Pyng Gau; Wen-Chien Chou; Rena Buckstein; Jaroslav Cermak; Ching-Yuan Kuo; Albert Oriol; Farhad Ravandi; Stefan Faderl; Jacques Delaunay; Daniel Lysák; Mark Minden; Christopher Arthur
Journal:  J Clin Oncol       Date:  2012-06-11       Impact factor: 44.544

6.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

7.  Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.

Authors:  Thomas Prebet; Zhuoxin Sun; Rhett P Ketterling; Amer Zeidan; Peter Greenberg; James Herman; Mark Juckett; Mitchell R Smith; Lisa Malick; Elisabeth Paietta; Magdalena Czader; Maria Figueroa; Janice Gabrilove; Harry P Erba; Martin S Tallman; Mark Litzow; Steven D Gore
Journal:  Br J Haematol       Date:  2015-11-18       Impact factor: 6.998

8.  DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.

Authors:  Maria E Figueroa; Sanne Lugthart; Yushan Li; Claudia Erpelinck-Verschueren; Xutao Deng; Paul J Christos; Elizabeth Schifano; James Booth; Wim van Putten; Lucy Skrabanek; Fabien Campagne; Madhu Mazumdar; John M Greally; Peter J M Valk; Bob Löwenberg; Ruud Delwel; Ari Melnick
Journal:  Cancer Cell       Date:  2010-01-07       Impact factor: 31.743

9.  Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.

Authors:  Mikkael A Sekeres; Megan Othus; Alan F List; Olatoyosi Odenike; Richard M Stone; Steven D Gore; Mark R Litzow; Rena Buckstein; Min Fang; Diane Roulston; Clara D Bloomfield; Anna Moseley; Aziz Nazha; Yanming Zhang; Mario R Velasco; Rakesh Gaur; Ehab Atallah; Eyal C Attar; Elina K Cook; Alyssa H Cull; Michael J Rauh; Frederick R Appelbaum; Harry P Erba
Journal:  J Clin Oncol       Date:  2017-05-09       Impact factor: 50.717

10.  Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.

Authors:  Gail J Roboz; Hagop M Kantarjian; Karen W L Yee; Patricia L Kropf; Casey L O'Connell; Elizabeth A Griffiths; Wendy Stock; Naval G Daver; Elias Jabbour; Ellen K Ritchie; Katherine J Walsh; David Rizzieri; Scott D Lunin; Tania Curio; Woonbok Chung; Yong Hao; James N Lowder; Mohammad Azab; Jean-Pierre J Issa
Journal:  Cancer       Date:  2017-12-06       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.